Neuro
Attention Deficit Disorder in Adults
search
Attention Deficit Disorder in Adults
, Adult ADHD, ADHD in Adults, Adult Attention Deficit Disorder
See Also
Attention Deficit Disorder in Children
School Problem Evaluation
ADHD Diagnosis
ADHD Differential Diagnosis
ADHD Comorbid Conditions
ADHD Non-Pharmacologic Management
ADHD Medication
s
Dextroamphetamine
(
Dexedrine
,
Dextrostat
,
Adderall
) or
Lisdexamfetamine
(
Vyvanse
)
Methylphenidate
(
Ritalin
,
Methylin
,
Concerta
)
Atomoxetine
(
Strattera
)
Epidemiology
Attention Deficit Disorder
of childhood continues into adulthood in up to 30% of cases
U.S.
Prevalence
has increased to 14.6% in 2022 (was estimated at 4.4% in 2006)
Adamis (2022) J Atten Disord 26(12): 1523-34 [PubMed]
Pathophysiology
See
Attention Deficit Disorder
Associated Conditions
See
ADHD Comorbid Conditions
Adults with Attention Deficit have a hIgher risk of complications
Unemployment
Educational underachievement
Financial problems
Substance Abuse
or misuse
Criminality
Accidents (MVA, workplace)
Differential Diagnosis
Decreased Attentiveness
See
ADHD Differential Diagnosis
Hearing Impairment
Thyroid
disorders
Liver
disease
Sleep Apnea
Traumatic Brain Injury
Mental health conditions
Anxiety Disorder
Major Depression
Bipolar Disorder
Obsessive Compulsive Disorder
Posttraumatic Stress Disorder
Substance Abuse
Personality Disorder
(
Antisocial Personality
,
Borderline Personality
)
Learning Disorder
s
Intellectual Disability
Medication adverse effects
Drug Interaction
s
Corticosteroid
s
Antihistamine
s
Anticonvulsants
Caffeine
Nicotine
Diagnosis
See
ADHD Diagnosis
Changes in DSM-V for diagnosis of ADHD in Adults
Onset of observed
ADHD
symptoms by age 12 years (instead of prior cirteria of onset age <7 years)
Lack of symptoms before age 12 years excludes
Attention Deficit Disorder
Five diagnostic criteria positive in either Inattention or Hyperactive categories (instead of prior 6 criteria required)
ADHD
Specific Diagnostic tools
Adult ADHD Self-Report Scale SymptomChecklist v1.1 (ASRS)
https://add.org/wp-content/uploads/2015/03/adhd-questionnaire-ASRS111.pdf
Contributing mental health conditions and collateral information
Obtain childhood medical records, school transcripts
DSM-5-TR self-rated level 1 cross-cutting symptom measure
https://unified.co.grant.wi.gov/wp-content/uploads/Symptom-Measure.pdf
Precautions
First degree ADHD
Family History
significantly increases
ADHD
likelihood
ADHD
patients may have high functioning in one area, while failing in other areas despite considerable effort
Evaluation
See
Attention Deficit Disorder
regarding history questions
Evaluate differential diagnosis (see above)
Evaluate for contraindications to
Stimulant Medication
s
See precautions below
Vital Sign
s
Blood Pressure
(evaluate for
Hypertension
)
Heart Rate
(evaluate for
Tachycardia
)
Electrocardiogram
Evaluate for
Arrhythmia
Variable recommendations as to whether to obtain
Electrocardiogram
prior to starting
Stimulant Medication
Management
Gene
ral
Same management and medications apply to adults as they do in children
See
ADHD Management
See
ADHD Medication
Consider mental health measures and counseling (esp. for those not meeting criteria for
ADHD Diagnosis
)
May consider neuropsychological diagnostic testing (often delayed months and costs >$1000)
Psychoeducational Counseling
Mindfulness
Cognitive remediation
Cognitive Behavioral Therapy
for adults with
ADHD
Young (2020) J Atten Disord 24(6): 875-88 [PubMed]
Other techniques with weaker evidence
Group dialectical behavioral therapy
Hypnotherapy
Management
Medications
Contraindications: Stimulants
Uncontrolled Hypertension
Coronary Artery Disease
Cardiomyopathy
Significant valvular heart disease
Tachycardia
Arrhythmia
Psychosis
Bipolar Disorder
Severe
Anorexia
Tourette Syndrome
Substance Abuse
Precautions:
Stimulant Use
in adults with comorbid heart disease
Sudden death events are reported at standard stimulant doses in adults and children
Wigal (2009) CNS Drugs 23(suppl 1): 21-31 [PubMed]
Large trials have demonstrated overall safety in adults without increased cardiovascular events or sudden death
Habel (2011) JAMA 306(24): 2673-8 [PubMed]
Precautions: Stimulant Diversion and Abuse
Stimulant Abuse
Simulants increase
Dopamine
levels transiently (associated with reward
Sensation
)
Overall
Stimulant Abuse
rate in adults: 2%
Stimulant Abuse
by adults aged 18 to 25 years: 4-6%
Non-
Cocaine
stimulant related deaths reached >32,000 in U.S. in 2021
Novak (2007) Subst Abuse Treat Prev Policy 2:32 [PubMed]
Diversion (giving or selling medications to others)
College student rate of use of non-prescribed stimulants: 8%
Prevention: Stimulant Diversion and Abuse
Initiate
Controlled Substance Agreement
(contract)
Implement random
Urine Drug Screen
ing every 3 months
Regular follow-up visits (e.g. every 6 months after the initial more frequent visits)
Review
Prescription Drug Monitoring Program
Adverse Effects: Stimulants
See
ADHD Medication
Hypertension
Tachycardia
Insomnia
Headache
s
Decreased appetite and weight loss
Mood Disorder
s (generalized anxiety,
Major Depression
)
Agent Selection
Once daily agents (e.g.
Adderall
XR,
Vyvanse
) may result in better compliance (compared with twice daily dosing)
Adult ADHD patients may see better efficacy and tolerability with
Amphetamine
-based agents to
Methylphenidate
Cortese (2018) Lancet Psychiatry 5(9): 727-38 [PubMed]
Clinic Visits
Schedule monthly visits until patients reach functional improvement
Evaluate
Blood Pressure
,
Heart Rate
, adverse effects and efficacy at each visits
Longterm follow-up at least every 6 months while medications are prescribed
Stopping medications
Risk of stimulant withdrawal (
Motor Tic
ks, confusion, irritability)
Consider tapering doses off for patients on higher dose stimulants
Medications
See
ADHD Medication
Amphetamine
s
See
Dextroamphetamine
Amphetamine
-
Dextroamphetamine
(
Adderall
)
Immediate Release: Start 5 mg orally once to twice daily (max: 40 mg/day)
Extended Release (XR): Start 10 to 20 mg orally each AM (max: 60 mg/day)
Dextroamphetamine
(Zenzedi, Xelstrym)
Immediate Release: Start 5 mg orally once to twice daily (max: 40 mg/day)
Patch
: Start 9 mg worn 9 hours on and 15 hours off (max: 18 mg on for 9 hours)
Lisdexamfetamine
(
Vyvanse
)
Start 30 mg orally once daily (max: 70 mg orally daily)
Methylphenidate
See
Methylphenidate
Non-
Stimulant Medication
s
Atomoxetine
(
Strattera
) or
Viloxazine
(
Qelbree
)
Effects may be delayed >1 month
Consider in comborbid
Anxiety Disorder
Bupropion
(
Wellbutrin
)
Consider in comorbid
Major Depression
or
Tobacco Cessation
References
Post (2012) Am Fam Physician 85(9):890-896 [PubMed]
Olagunju (2024) Am Fam Physician 110(2): 157-66 [PubMed]
Type your search phrase here